Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 7 people — 3 in Cohort 1 and 4 in Cohort 2. The trial was measuring specific dose-related side effects (called dose-limiting toxicities) of an investigational treatment, as well as how quickly the treatment left the body and whether participants developed a particular immune response to it (called Human Anti-Human Antibodies, or HAHA — meaning the body producing proteins that react against the treatment). The reported data shows that none of the participants in either cohort experienced a dose-limiting toxicity — that is, none experienced the specific serious side effects the trial was designed to look for and count. Regarding how quickly the treatment cleared from the body, the reported half-life (the time it took for half of the treatment to leave the bloodstream) was approximately 2.43 days for Cohort 1 and 2.28 days for Cohort 2. The reported data also shows that none of the participants in either cohort developed the immune response (HAHA) that was being monitored. It is worth noting that only 4 of the 7 participants completed the trial overall — all 3 in Cohort 1 completed it, while only 1 of the 4 in Cohort 2 did, with 3 in that cohort not completing. The reasons for not completing were not included in the data provided here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 1 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with a specific type of ovarian cancer (non-mucinous ovarian adenocarcinoma), confirmed by a lab test on tissue.
- Your ovarian cancer (Stage 3) has come back or has not fully gone away after treatment with platinum- and taxane-based chemotherapy, and the cancer is inside the abdomen.
- The remaining cancer in your body is smaller than 2 cm (about the size of a small grape).
- Your recent blood tests and other lab results (taken within the last 2 weeks) show that your blood counts, liver, kidney, lung, and heart function are all within acceptable ranges (confirm specific values with trial site).
- You are generally able to carry out normal daily activities, as measured by a standard health performance scale (Karnofsky score of 70 or above).
- You are willing and able to sign a written consent form agreeing to take part in the trial.
- You are able to have a small tube (catheter) placed inside your abdomen during surgery as part of the treatment.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Your cancer has spread to organs outside the abdomen (Stage IV disease).
- You have cancer that has spread outside the abdomen and is causing symptoms.
- The cancer has spread to your brain or spinal cord.
- You have significant heart disease that limits your daily activities (confirm with trial site).
- A recent heart test (ECG) shows a serious irregular heartbeat or signs of a previous heart attack.
- You have other serious health conditions, such as an active serious infection requiring antibiotics, or a bleeding disorder that may make surgery or the treatment unsafe.
- You have a long-term inflammatory bowel condition (such as Crohn's disease or ulcerative colitis).
- You have received chemotherapy, biological therapy, or immunotherapy within the last 4 weeks before joining the trial.
- You are currently pregnant or breastfeeding.
- You have previously received a certain type of antibody treatment (murine monoclonal antibody), or a blood test shows your immune system may react against the treatment used in this trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Number of Patients With Dose-limiting Toxicities (DLTs)
Other options
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.